Aclaris Therapeutics, Inc. Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • November 18th, 2016 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • New York
Introductory. Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,000,000 shares of its common stock, par value $0.00001 per share (the “Shares”). The 4,000,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 600,000 Shares as provided in Section 2. The additional 600,000 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies LLC (“Jefferies”) and Leerink Partners LLC (“Leerink”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the e
